Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 1,882 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 1,882 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $18.15, for a total value of $34,158.30. Following the completion of the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,638,193.25. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.55, for a total value of $330,097.25.
• On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $10,980.75.

Bicara Therapeutics Stock Down 1.9%

Shares of BCAX traded down $0.32 during trading hours on Monday, hitting $16.42. 567,617 shares of the company were exchanged, compared to its average volume of 484,589. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $19.71. The company has a market cap of $899.49 million, a price-to-earnings ratio of -7.33 and a beta of -0.79. The firm’s fifty day moving average is $17.45 and its 200 day moving average is $14.72.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.12). Analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vestal Point Capital LP increased its holdings in Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after purchasing an additional 100,000 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock valued at $34,753,000 after buying an additional 195,667 shares during the period. Millennium Management LLC increased its stake in shares of Bicara Therapeutics by 37.0% in the third quarter. Millennium Management LLC now owns 1,014,892 shares of the company’s stock valued at $16,025,000 after buying an additional 273,873 shares during the period. Geode Capital Management LLC raised its holdings in Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after buying an additional 180,833 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its position in Bicara Therapeutics by 91.8% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 504,085 shares of the company’s stock worth $7,959,000 after buying an additional 241,334 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on BCAX. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Mizuho raised Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.